Gaea | Clinical Ltd
One Broadcarr Road
SK11 0AQ
United Kingdom

Gaea Clinical Trial Services LLC
97343, Saint-Petersburg,
ul. Matrosa Zheleznyaka, 57A, 122N

Tel: +44 1625 413 900
Fax: +44 1452 798 222
Mobile: +49 151 51 11 19 31

Market assessments

The principles of European healthcare are that it is free (or virtually free) at the point of delivery, and that interventions that meet an unmet medical need are reimbursed. However, there is not enough money in any European healthcare system to pay for all interventions, so how can purchasers decide what to accept?

Gaea has conducted market assessments of commercial drugs and NCEs, particularly orphan and ultra-orphan drugs that have so far stayed under the government's cost 'radar'. We can help define the size of the future market for these very high cost drugs and assist with the client's understanding of the impact of government pricing and reimbursement policies in the context of increased resource rationing in Europe.

Our in-house analysts will conduct a potential product analysis using an agreed ideal product concept, with the goal to ensure that an NCE will meet an actual market need and to define the extent of that need. This will include the most appropriate target population, their unmet medical needs, the market size and future competition, current limits on prescribers and the prospects for future barriers to adoption.

Gaea's recent work in orphan and ultra-orphan indications includes:

  • Eculizumab in paroxysmal nocturnal hemoglobinuria
  • Ivacaftor in cystic fibrosis
  • Alglucosidase alfa in Pompe disease
  • An NCE in sickle cell anaemia

Our Recent Clients

Glycotope GmbH
DNAtrix Inc.
Genelux GmbH
Vifor Pharma UK Ltd
CureVac GmbH
MucoVax GmbH
BN ImmunoTherapeutics
Oncolytics Biotech Inc.
Cougar Biotech Inc.
Agios Inc.
Drug Royalty International
Allos Therapeutics Inc.
The Medicines Company, Inc.
Adventrx Inc.
Baxter Bioscience, Inc.
Merck Serono Oncology

Read More